MOTS-C (20 mg Vial)

MOTS-C Research Reference

MOTS-C is referenced at 200 mcg–1 mg daily via subcutaneous application in educational research settings. A 20 mg vial prepared with bacteriostatic water provides approximately 6.67 mg/mL. Research references describe gradual adjustment over roughly 10 weeks. This information is provided for research and educational use only.

MOTS-C is a 16-amino-acid mitochondrial-derived peptide (MDP) that acts as a metabolic regulator, primarily through AMPK activation. Preclinical studies show roles related to insulin sensitivity, fat oxidation, exercise capacity, and age-related metabolic pathways. No clinical trials have been completed in humans to date. This educational reference presents a once-daily subcutaneous approach with gradual adjustment.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety information, read MOTS-C Peptide: Benefits, Uses, Research Background.

Educational guide for preparation and daily reference information

Standard / Gradual Approach (3 mL = ~6.67 mg/mL)

Week	Daily Amount (mcg)	Units (per administration) (mL)
Weeks 1–2	200 mcg (0.2 mg)	3 units (0.03 mL)
Weeks 3–4	400 mcg (0.4 mg)	6 units (0.06 mL)
Weeks 5–6	200 mcg600 mcg (0.6 mg)	12 units (0.12 mL)
Weeks 7–8	250 mcg800 mcg (0.8 mg)	12 units (0.12 mL)
Weeks 9–10+	1,000 mcg (1.0 mg)	15 units (0.15 mL)

Frequency: Apply once daily subcutaneously. Stay at each reference level for approximately 2 weeks before increasing, and monitor for any adverse responses.

For ≤10-unit (≤0.10 mL) applications, consider 30- or 50-unit measurement devices for improved readability.

Preparation Steps

Important: This guide is for educational purposes only and is not medical advice.

Plan based on an 8–16 week daily research schedule with gradual adjustment.

Concise summary of the once-daily research schedule.

Goal: Support metabolic homeostasis, insulin sensitivity, and age-related physical performance based on preclinical evidence.
Schedule: Daily subcutaneous application for 8–12 weeks (extend to 16 weeks if desired).
Reference Range: 200–1,000 mcg daily with gradual adjustment over 10 weeks.
Preparation: 3.0 mL per 20 mg container (~6.67 mg/mL) for accurate measurement reference.
Storage: Lyophilized material stored at −20 °C (−4 °F); prepared solution refrigerated at 2–8 °C (35.6–46.4 °F); avoid repeated freeze–thaw cycles.

Suggested daily adjustment approach based on animal-to-human research references.

Start: 200 mcg daily for 2 weeks.
Adjustment: Increase by ~200 mcg every 2 weeks: 400 mcg (Weeks 3–4), 600 mcg (Weeks 5–6), 800 mcg (Weeks 7–8).
Reference Target: Up to 1,000 mcg (1.0 mg) daily by Weeks 9–10+ if well tolerated.
Frequency: Once per day (subcutaneous).
Cycle Length: 8–12 weeks; optional extension to 16 weeks.
Timing: Any consistent time; rotate application areas.

Proper storage preserves peptide quality and stability.

Lyophilized: Store at −20 °C (−4 °F) or below in dry, dark conditions; include desiccant if available to minimize moisture exposure.
Prepared: Refrigerate at 2–8 °C (35.6–46.4 °F); peptide stability may reduce at room temperature. Use within 7 days for best stability.
Aliquoting: Prepare single-use portions and freeze at −20 °C (−4 °F) if needed; avoid freeze–thaw cycles.

Allow containers to reach room temperature before opening to reduce condensation uptake.

Practical considerations for consistency and safety.

Use: Use new sterile measurement devices for each application; dispose of used items in a proper sharps container.
Rotation: Rotate application areas (abdomen, thighs, upper arms) to reduce local irritation and prevent tissue changes.
Application: Apply slowly; wait a few seconds before removing the needle.
Documentation: Record daily reference amount, application area, and observations to maintain consistency.
Safety: Discontinue use and consult a medical professional if any concerning symptoms arise.

MOTS-C functions as a metabolic “stress signal” that helps optimize energy usage during nutrient stress or exercise. Its primary mechanism is AMPK activation through inhibition of the folate cycle, causing accumulation of AICAR (an AMP analog). Activated AMPK shifts cells into an energy-efficient mode — enhancing glucose uptake, fatty-acid oxidation, and mitochondrial respiration while downregulating fat storage and gluconeogenesis. MOTS-C can also translocate to the cell nucleus under stress conditions and regulate antioxidant and stress-response genes. This retrograde signaling from mitochondria to nucleus increases expression of cytoprotective enzymes, helping cells cope with oxidative stress. Research indicates MOTS-C may also influence mTOR and inflammatory pathways, contributing to lifespan and healthspan effects. Its actions resemble those of exercise and metformin at a cellular level, making it of interest for metabolic disorders, obesity, and aging research.

Observations from preclinical literature (no human clinical trials completed to date).

Metabolic Health: Improves insulin sensitivity and glucose metabolism in mouse models; supports metabolic balance and reduces diet-induced insulin resistance.
Weight & Fat Reduction: Supports weight management research and reduces visceral fat in obese mice through increased energy expenditure and fat oxidation.
Post-Menopausal Metabolism: Supports metabolic regulation in ovariectomized mice; influences menopause-related fat gain and insulin resistance pathways.
Physical Performance: Supports exercise capacity and age-related physical function in research models.
Organ Protection: Supports liver fat regulation, cardiac function, and may influence cognitive function in preliminary studies.
Bone & Immunity: Supports osteoblast activity, influences osteoclast formation, affects immune aging pathways, and protects pancreatic islet cells in autoimmune diabetes models.
Safety: No adverse effects reported in preclinical studies; human tolerability remains unknown. A modified analog (CB4211) showed good tolerability in a Phase 1 trial.
Note: These findings have been demonstrated only in controlled research settings (mice or cells). Translation to humans requires clinical studies.

Complementary strategies for best outcomes based on MOTS-C’s metabolic mechanisms.

Nutrition: Pair with a balanced, protein-forward diet tailored to energy needs.
Exercise: Combine resistance training and aerobic activity to reinforce metabolic adaptations and AMPK signaling.
Sleep: Prioritize sleep (7–9 hours) and stress management to support mitochondrial health and recovery.
Fasting: Consider intermittent fasting or caloric restriction, which may influence MOTS-C related metabolic effects.

General subcutaneous guidance from clinical best-practice resources.

Site Preparation: Clean the container stopper and skin area with alcohol; allow to dry completely.
Application Position: Pinch a skinfold; insert the needle at 90° (45° if very lean) into subcutaneous tissue.
Administration: Do not aspirate for subcutaneous applications; apply slowly and steadily over a few seconds.
After Application: Withdraw the needle at the same angle; apply gentle pressure if bleeding occurs (do not rub).
Site Rotation: Rotate areas systematically (abdomen at least 2 inches from navel, outer thighs, back of upper arms) to avoid irritation and tissue changes.
Disposal: Dispose of used devices immediately in a proper sharps container (never reuse needles).

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. MOTS-C is an experimental compound; no clinical trials have been completed in humans. Always consult qualified healthcare providers before starting any new therapy.

Cell Metabolism (2015)

— The mitochondrial-derived peptide MOTS-C promotes metabolic homeostasis and reduces obesity and insulin resistance (Lee C, Zeng J, Drew BG, et al.)

Journal of Translational Medicine (2023)

— Mitochondria-derived peptide MOTS-C: effects and mechanisms related to stress, metabolism and aging (Wan W, Zhang L, Lin Y, et al.)

Journal of Molecular Medicine (2019)

— MOTS-C peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction (Lu H, Wei M, Zhai Y, et al.)

Nature Communications (2021)

— MOTS-C is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis (Reynolds JC, Lai RW, Woodhead JST, et al.)

Frontiers in Physiology (2023)

— Role of MOTS-C in the regulation of bone metabolism (Yi X, Hu G, Yang Y, et al.)

USADA Spirit of Sport (2023)

— What is the MOTS-C peptide? – U.S. Anti-Doping Agency education article

CDC Vaccine Administration Guidelines

— Subcutaneous route guidance (angle, site selection, no aspiration)